This thesis examines the mediation of ecological values, showing that we come to understand, interact, and value the ecologies in which we are bound, through experience of commodified and technologised abstractions of ecological life. So doing, I take the study of ecological value out of the natural and into the cultural, because it is within the sphere of culture that such ecological values are propagated and valiorised. And it is those values that determine how we act on, in, and through our environments, and ultimately come to engage as active ecological agents.

Background: Calcium channel blockers are mainly divided into antihypertensive and antianginal treatment agents. In 2000 it was estimated that 972 million adults worldwide were living with hypertension and it is expected to affect 1.56 billion patients by 2025. The incremental expenditure for the antihypertensive therapeutic group in the United States of America was estimated at $US 55 billion per annum in 2006. It was stated that around seven million people in the United States of America suffered from angina, with around 400 000 new reports every year. Objective: To determine the prescribing patterns of calcium channel blocker medicine items during 2005 to 2008 in a section of the private health care sector of South Africa. Methods: A retrospective quantitative drug utilisation review was done using a medicine claims database ranging over four years from 1 January 2005 to 31 December 2008. The total medicine claims database was divided into cardiovascular medicine items and then into calcium channel blockers. These were analysed according to age as well as gender. Further analysis included adherence of calcium channel blockers as well as an analysis of prescribers of these items during the study period. Results: The total number of patients on the medicine claims database consisted of 1 509 621 patients in 2005. This number decreased to 974 497 patients in 2008. The most medicine items were dispensed in 2006 (n = 21 113 422) with an average cost of R 92.82 (SD = 196.42) per medicine item. It was noted that 16.05% (n = 242 264) of patients used at least one cardiovascular item in 2005. The percentage of cardiovascular medicine item users increased by 4.36% during the study period to 20.41% (n = 198 847) in 2008. In 2008 the cardiovascular medicine items dispensed were responsible for 19.18% (R 342 565 308.41) of the total cost of all medicine items claimed. In 2005 the results revealed that 1.63% (n = 318 258) of all medicine items dispensed were calcium channel blocker medicine items. The percentage of calcium channel blockers increased to 2.24% (n = 367 437) of the total number of medicine items in 2008. The cost prevalence index was calculated for the calcium channel blockers and the value declined from 1.5 in 2005 to 1.22 in 2008, which indicated that the items dispensed were relatively expensive, but less than in 2005. An increase of 16.17% in the usage of generic medicine items were noted from 2005 to 2008. More female patients than male patients claimed medicine items during the study period. A higher percentage of male patients used a cardiovascular medicine item as well as calcium channel blockers during the study period compared to females and a larger percentage of their medicine expenditure was used on cardiovascular medicine items as well as calcium channel blockers compared to females. The usage of cardiovascular medicine items as well as calcium channel blocker medicine items increased with patient age. In 2008, 17.98% of patients older than 65 years of age used a calcium channel blocker compared to 0.97% of patients aged > 25 <= 35 years. Only 60.34% of calcium channel blockers items were used with acceptable refill adherence rates during the study. More than a third of the calcium channel blockers medicine items used had unacceptable low adherence rates from 2005 to 2008. In each of the study years the highest potential saving with generic substitution was seen with amlodipine containing items. It was also observed that some generic substitutions could be relatively more expensive than the innovator products and an increased cost instead of a saving through generic substitution may have occurred. Conclusion: This study highlighted the prescribing patterns and cost implications of calcium channel blockers in the private health care sector of South Africa. It is recommended that a more in–depth study of the adherence of calcium channel blockers be done. This study should also include the cost strategies of generic substitution of calcium channel blockers in South Africa. / Thesis (M.Pharm (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2011.

Background: Calcium channel blockers are mainly divided into antihypertensive and antianginal treatment agents. In 2000 it was estimated that 972 million adults worldwide were living with hypertension and it is expected to affect 1.56 billion patients by 2025. The incremental expenditure for the antihypertensive therapeutic group in the United States of America was estimated at $US 55 billion per annum in 2006. It was stated that around seven million people in the United States of America suffered from angina, with around 400 000 new reports every year. Objective: To determine the prescribing patterns of calcium channel blocker medicine items during 2005 to 2008 in a section of the private health care sector of South Africa. Methods: A retrospective quantitative drug utilisation review was done using a medicine claims database ranging over four years from 1 January 2005 to 31 December 2008. The total medicine claims database was divided into cardiovascular medicine items and then into calcium channel blockers. These were analysed according to age as well as gender. Further analysis included adherence of calcium channel blockers as well as an analysis of prescribers of these items during the study period. Results: The total number of patients on the medicine claims database consisted of 1 509 621 patients in 2005. This number decreased to 974 497 patients in 2008. The most medicine items were dispensed in 2006 (n = 21 113 422) with an average cost of R 92.82 (SD = 196.42) per medicine item. It was noted that 16.05% (n = 242 264) of patients used at least one cardiovascular item in 2005. The percentage of cardiovascular medicine item users increased by 4.36% during the study period to 20.41% (n = 198 847) in 2008. In 2008 the cardiovascular medicine items dispensed were responsible for 19.18% (R 342 565 308.41) of the total cost of all medicine items claimed. In 2005 the results revealed that 1.63% (n = 318 258) of all medicine items dispensed were calcium channel blocker medicine items. The percentage of calcium channel blockers increased to 2.24% (n = 367 437) of the total number of medicine items in 2008. The cost prevalence index was calculated for the calcium channel blockers and the value declined from 1.5 in 2005 to 1.22 in 2008, which indicated that the items dispensed were relatively expensive, but less than in 2005. An increase of 16.17% in the usage of generic medicine items were noted from 2005 to 2008. More female patients than male patients claimed medicine items during the study period. A higher percentage of male patients used a cardiovascular medicine item as well as calcium channel blockers during the study period compared to females and a larger percentage of their medicine expenditure was used on cardiovascular medicine items as well as calcium channel blockers compared to females. The usage of cardiovascular medicine items as well as calcium channel blocker medicine items increased with patient age. In 2008, 17.98% of patients older than 65 years of age used a calcium channel blocker compared to 0.97% of patients aged > 25 <= 35 years. Only 60.34% of calcium channel blockers items were used with acceptable refill adherence rates during the study. More than a third of the calcium channel blockers medicine items used had unacceptable low adherence rates from 2005 to 2008. In each of the study years the highest potential saving with generic substitution was seen with amlodipine containing items. It was also observed that some generic substitutions could be relatively more expensive than the innovator products and an increased cost instead of a saving through generic substitution may have occurred. Conclusion: This study highlighted the prescribing patterns and cost implications of calcium channel blockers in the private health care sector of South Africa. It is recommended that a more in–depth study of the adherence of calcium channel blockers be done. This study should also include the cost strategies of generic substitution of calcium channel blockers in South Africa. / Thesis (M.Pharm (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2011.

En m’appuyant sur la sociologie des attentes technoscientifiques et les études critiques du handicap, j’analyse dans cette thèse l’expérience de personnes diagnostiquées comme obèses ou obèses « morbides » ayant subi une chirurgie bariatrique (ou de perte de poids). Alors que la lutte contre l'obésité a longtemps mis l’accent sur les changements de mode de vie, les discours de santé publique ont pris un ton plus urgent à partir des années 2000, qualifiant l’obésité d’« épidémie » justifiant des interventions radicales. Parallèlement, le stigmate contre la graisse corporelle s’est intensifié, et le nombre de chirurgies bariatriques a connu une croissance exponentielle, notamment chez les femmes. Je défends que ces phénomènes concomitants doivent être interprétés dans le contexte d’une « économie de l’espoir » qui englobe les anticipations des promoteurs de la santé publique, des chercheurs en obésité et chirurgiens bariatriques, des personnes en situation d’obésité, et de leurs proches. Au sein de cette dynamique, la clinique bariatrique devient un lieu où se croisent et se heurtent plusieurs définitions de l’« obésité » et différentes priorités de santé. En me basant sur des entretiens semi-directifs menés avec des patientes bariatriques et des cliniciens, j’explore comment les patientes qui s’est manifesté de manière à la fois discursive, émotionnelle et matérielle, influençant leurs adoptent, rejettent ou réinterprètent les notions médicalisées de l’obésité. Je le fais en examinant les motivations des personnes en obésité à subir une chirurgie bariatrique, ainsi que les transformations physiques, physiologiques, identitaires et sociales qui découlent de ce processus. Je fais valoir que la décision de recourir à la chirurgie de perte de poids n’a pas pour seul objectif l’amélioration de leur santé actuelle et future, mais vise également à obtenir une corpulence conforme aux normes sociales, qui leur permet d’accéder à certains espaces communs et partagés et de remplir des rôles sociaux spécifiques. Je montre que les participantes ont fait l'expérience d’un stigmate attentes à l’égard de la chirurgie, ainsi que leurs expériences de ses effets multiples et parfois contradictoires. J’analyse comment cet objectif de normalisation corporelle est atteint au prix de l’acquisition de nouvelles formes de chronicité, dont la gestion reconfigure le rôle de la patiente et la relation entre la patiente et le médecin. En analysant les contradictions propres à la clinique de l’obésité, cette analyse réinterprète le processus de biomédicalisation comme une logique de substitution ou de déplacement de la chronicité plutôt que de normalisation ou d’optimisation. / Drawing on the sociology of technoscientific expectations and critical disability studies, this thesis investigates the experiences of individuals diagnosed with obesity or morbid obesity who have undergone bariatric (weight loss) surgery. While the fight against obesity has long emphasized lifestyle changes, public health discourse has taken on a more urgent tone since the early 2000s, labeling obesity as an "epidemic” justifying radical interventions. Concurrently, the stigma against excess body weight has intensified, and the number of bariatric surgeries has grown exponentially, particularly among women. I argue that these concurrent phenomena should be understood within the framework of an "economy of hope" that encompasses the expectations of public health advocates, obesity researchers, bariatric surgeons, individuals with obesity, and their closed ones. Within this dynamic, the bariatric clinic becomes a site where multiple definitions of "obesity" and different health priorities intersect and collide. Using semi-structured interviews with bariatric patients and clinicians, I investigate how patients either adopt, reject, or reinterpret medicalized notions of obesity. I achieve this by examining the motivations of individuals with obesity for choosing bariatric surgery and the ensuing physical, physiological, identity, and social transformations. I argue that the decision to undergo weight loss surgery is not solely driven by a desire to enhance current and future health but also to attain a body shape that aligns with societal norms, enabling access to shared spaces and the fulfillment of specific social roles. I demonstrate that participants experience a stigma that manifests itself in discursive, emotional, and material ways, shaping their expectations regarding surgery and their experiences of its multifaceted and at times contradictory effects. I analyze how the pursuit of bodily normalization leads to the acquisition of new forms of chronicity, which, in turn, reshapes the patient's role and the patient-physician relationship. By highlighting the contradictions within the clinic of obesity, this analysis reinterprets the process of biomedicalization as a logic of substitution or shifting chronicity rather than normalization or optimization.